Stock Analiz

SAB Biotherapeutics, Inc. SABS

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$2.96Market cap $267M
Open the interactive analysis →

SAB Biotherapeutics, Inc. (SABS) is a healthcare company listed in the US with a market value of about $267M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -64%.

About SAB Biotherapeutics

SAB Biotherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $55M in 2020 to $1M in 2024, a decline of about 60.7% a year. It was profitable in 2 of the last 6 years in our data. Its share count rose by 1309% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-17.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1142.5%
ROIC (5-yr avg.)-64.0%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue—$1M$2M$24M$61M$55M
Net income$13M-$34M-$42M-$19M-$17M$20M
Free cash flow-$46M-$35M-$25M-$26M-$9M-$3M
EPS (diluted)$-0.79$-3.68$-7.64$-4.31$-6.30$7.40
Net margin—-2579.0%-1884.5%-78.4%-28.2%36.4%
ROIC-31.8%-124.5%-63.8%-68.8%-31.0%47.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 11 analysts is $11.64, 293% above the current price; targets range from $6.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-1.13 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does SAB Biotherapeutics pay a dividend?

Not currently.

Is SAB Biotherapeutics a good stock to buy?

We do not give buy or sell advice. SAB Biotherapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.